Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
The physical stability of an immunoglobulin G4 monoclonal antibody (mAb) upon dilution into intravenous (i.v.) bags containing 0.9% saline was examined. Soluble aggregates and subvisible particles were observed by size-exclusion high-performance liquid chromatography (SE-HPLC) and light obscuration when formulated with suboptimal levels of polysorbate 20. The formation of soluble aggregates and particulates was further characterized by a combination of SE-HPLC, nanoparticle tracking analysis (NTA), microflow-digital imaging (MFI), and turbidity measurements. With sufficient PS20 levels, particle formation was minimized, although quantification of submicron sized particles by NTA was not possible because of the interference from PS20. Intravenous bags composed of polyvinyl chloride caused more protein particle formation than polyolefin bags. Differences between bag types were affected by removing headspace and by transferring the saline solution into glass vials. Characterization studies with Fourier transform infrared microscopy and extrinsic fluorescence spectroscopy demonstrated that isolated particles contained native-like secondary structure with partially altered tertiary structure, compared with heat-denatured and nonstressed controls. Transmission electron microscopy and MFI analysis showed particles had an amorphous morphology of varying sizes. Particles contained some non-native disulfide bond crosslinks, potentially initiated by low levels of free thiol in the native mAb. The critical role of proper formulation design to stabilize proteins against physical instability during i.v. administration is discussed.
Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, Kansas 66047, USA.
Ozan S
OS
Kumru
Jun
J
Liu
Junyan A
JA
Ji
Wilson
W
Cheng
Y John
YJ
Wang
Tingting
T
Wang
Sangeeta B
SB
Joshi
C Russell
CR
Middaugh
David B
DB
Volkin
D061605:Administration, Intravenous / Q000379:methods; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry* / Q000276:immunology*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004355:Drug Stability; D004356:Drug Storage; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D007262:Infusions, Intravenous / Q000379:methods; D009391:Nephelometry and Turbidimetry; D010316:Particle Size; D017434:Protein Structure, Tertiary; D011506:Proteins / Q000737:chemistry
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D011506:Proteins